A Rare Presentation of Multi-System Inflammatory Disease in Children Associated With Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2)

Shayan Makvandi 1, Omar Alibrahim 2, Rabheb Abdul-Aziz 2, Mohammad Abdul-Fattah Sallam 2, Megan McGreevy 4

1. Department of Pediatrics, Oishei Children’s Hospital/University at Buffalo, Buffalo, USA 2. Pediatric Critical Care, Oishei Children’s Hospital/University at Buffalo, Buffalo, USA 3. Department of Pediatric Rheumatology, Oishei Children’s Hospital/University at Buffalo, Buffalo, USA 4. Pediatric Cardiology, Oishei Children’s Hospital/University at Buffalo, Buffalo, USA

Corresponding author: Shayan Makvandi, shayanma@buffalo.edu

Abstract

Management of multi-system inflammatory disease in children (MIS-C) remains a challenge due to the evolving nature of the coronavirus disease 2019 (COVID-19) pandemic. This article reports a rare presentation of multi-system inflammatory disease in a previously healthy 16-month-old male who fully recovered with minimal residual cardiac insufficiency upon discharge. Our case is unique due to patient’s young age, cardiac findings, and his response to our treatment protocol. A multi-disciplinary team in a tertiary center was involved with care.

Introduction

Since April 2020, multiple reports emerged from Europe and later from New York of multi-system inflammatory disease in children (MIS-C) presenting with different clinical patterns that occur from one to six weeks following severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection in the pediatric age group [1-8]. Different clinical patterns were reported, including Kawasaki disease (KD)-like illness, vasoplegic shock, cardiogenic shock/myocarditis, and hyperinflammatory clinical pattern with the absence of shock and mucocutaneous involvement [2]. Cardiac involvement was variable among reports with suggested pathophysiology of cardiac edema rather than acute necrotic inflammatory myocardial injury [1]. Cardiac magnetic resonance imaging (MRI) examination supported this theory by finding little evidence of myocardial cell degeneration and necrosis [9]. The median age of affected children with MIS-C is reported to be consistently older than children affected by KD (mean: 8.5 - 10) [5, 1]. Evidence of SARS-CoV-2 infection was also variable among the reports, ranging from 69% to 100% [4-6].

Case Presentation

A previously healthy 16-month-old male presented with febrile seizure, rash, and diarrhea. Initial workup in the emergency room, including a CT scan of the head, was not conclusive. He was sent home and returned 12 hours later with 40.4 C fever, worsening upper body rash, and diarrhea. Vital signs were significant for heart rate 120, hypotensive with blood pressure 72/40, tachypneic with respiratory rate 36, and oxygen saturation of 99% while breathing ambient air. Physical exam was prominent for periorbital edema, hepatomegaly 4cm below the right costal margin, bilateral inguinal lymphadenopathy, and slightly raised satiuation.

Shortly after admission, he developed distributive shock with worsening hypotension and tachycardia. The patient was intubated with concern for acute hypoxic respiratory failure and shock state. Vasopressors and inotropes were initiated for hypotension. Blood and urine cultures were obtained, and broad-spectrum antibiotics with cefepime and vancomycin were started. Patient met Centers for Disease Control and Prevention (CDC) criteria for MIS-C with fever, anemia hemoglobin 8.8 g/dL, hypoalbuminemia 2.7 g/dL, thrombocytopenia 69 x10^9/L, elevated C-reactive protein 134 mg/L, erythrocyte sedimentation rate 10mm/hr, elevated procalcitonin 33.9 ng/mL, elevated ferritin 2765 ng/mL, elevated lactic acid dehydrogenase 987 u/L, IL6 318pg/mL, IL2 4705pg/mL, IL10 38pg/mL, coagulopathy with significantly elevated D-dimer 18 mcg/mL, prolonged prothrombin time (PT) 17.9 sec, prolonged partial thromboplastin time (PTT) 39.3 sec, elevated brain natriuretic peptide (BNP) 498 pg/mL and low anti-thrombin III 39, positive COVID-19 immunoglobulin G (IgG) antibody and negative polymerase chain reaction (PCR). The rapid viral panel was negative. Serial echocardiograms showed hyperdynamic left ventricle systolic function and mild tricuspid regurgitation with no clinical significance and ultimately resolved (Figures 1-2). EKG
showed nonspecific t-wave changes. Troponin was within a normal range. The patient received methylprednisolone 20mg/kg, anakinra 2mg/kg, intravenous immunoglobulin (IVIG) 2g/kg, and prophylactic Lovenox® dosing with 0.5mg/kg twice daily. The patient remained intubated on mechanical ventilation and remained on vasopressors/inotropes for three days with a maximum epinephrine dose of 0.08 mcg/kg/min and norepinephrine 0.15 mcg/kg/min. Anakinra dosage was gradually increased over time due to persistent fevers. The patient completed 12 days of anakinra with a maximum dosing of 12mg/kg/day, two doses of IVIG, and was maintained on a high dose of methylprednisone 30 mg/kg/day on the second and third days and then 8mg/kg/day with tapering for the rest of stay, which switched to oral prednisone once oral tolerance improved. The patient stayed at the hospital for a total of 15 days and was discharged on steroid taper. Laboratory data for the initial 10 days of admission are presented in Table 1.

FIGURE 1: Tricuspid valve regurgitation

FIGURE 2: Mitral valve regurgitation
| Date | 6/6 | 6/7 | 6/8 | 6/9 | 6/10 | 6/11 | 6/12 | 6/13 | 6/15 | 6/18 |
|------|-----|-----|-----|-----|------|------|------|------|------|------|
| WBC x10^9/L | 7.7 | 5.5 | 8.5 | 7.2 | 12.6 | 12.9 | 12.1 | 15.0 | 10.1 | 12.2 |
| Hgb x10^12/L | 8.0 | 6.2 | 7.6 | 8.1 | 8.3 | 9.1 | 9.3 | 9.0 | 9.3 | 8.7 |
| Platelets x10^9/L | 69 | 68 | 73 | 102 | 202 | 248 | 306 | 397 | 382 | 336 |
| Neutrophils/ 100 leukocyte | 44 | 62 | 66 | 66 | 61 | 61 | 67 | 37 | 42 | 34 |
| Lymphocyte/ 100 leukocyte | 18 | 35 | 28 | 28 | 32 | 25 | 13 | 17 | 15 | 14 |
| Monocytes/ 100 leukocyte | 1 | 1 | 1 | 4 | 3 | 10 | 13 | 17 | 15 | 14 |
| ESR (mm/hr) | 10 | 22 | - | 21 | - | 18 | 19 | 12 | - | - |
| Ferritin (ng/mL) | 2763 | 4465 | 2566 | 2367 | 1402 | 1184 | 1182 | 774 | 496 | 238 |
| PT (sec) | 16.9 | 15.9 | 14.2 | 13.8 | 14.3 | 14.1 | 15.1 | - | - | - |
| PTT (sec) | 39.3 | 45.4 | 42.6 | 33.1 | 27.9 | 27.3 | 31.1 | - | - | - |
| Fibrinogen | 309 | 315 | - | 151 | - | 141 | 103 | 125 | 131 | - |
| D-dimer (mcg/mL) | 18.27 | 14.78 | - | 14.22 | - | 18.1 | - | 6.37 | 2.2 | 1.02 |
| Antithrombiin III level | 39 | - | 52 | 78 | 92 | 97 | 92 | - | - | - |
| Sodium (mmol/L) | 138 | 139 | 138 | 142 | 140 | 140 | 135 | - | 137 | - |
| Potassium (mmol/L) | 4.0 | 3.1 | 2.6 | 3.1 | 3.3 | 4.5 | 4.8 | - | 4.7 | - |
| Chloride (mmol/L) | 115 | 112 | 106 | 103 | 102 | 106 | 103 | - | 104 | - |
| Carbon dioxide (mmol/L) | 15 | 14 | 20 | 27 | 27 | 25 | 23 | - | 23 | - |
| BUN (mg/dL) | 11 | 9 | 14 | 10 | 11 | 13 | 11 | - | 19 | - |
| Creatinine (mg/dL) | 0.36 | 0.37 | 0.53 | 0.47 | 0.42 | 0.45 | 0.45 | - | 0.43 | - |
| Calcium (mg/dL) | 6.6 | 6.4 | 6.9 | 7.3 | 8.1 | 8.6 | 8.7 | - | 9.2 | - |
| Phosphate (mg/dL) | 1.2 | 2 | 2.5 | 1.7 | 2.3 | 3.3 | 4.5 | - | - | - |
| Magnesium (mg/dL) | 1.6 | 1.7 | 1.7 | 1.8 | 1.8 | 1.9 | 2.1 | - | - | - |
| Lactate (mmol/L) | 4 | 1.2 | 0.9 | 0.9 | 1.2 | - | - | - | - | - |
| Bilirubin (mg/dL) | 3.5 | 1.5 | 1.6 | 1.9 | - | - | - | - | - | - |
| AST (unit/L) | 104 | 83 | 50 | 55 | - | - | - | - | - | - |
| ALT (unit/L) | 85 | 66 | 36 | 41 | - | - | - | - | - | - |
| LDH (unit/L) | 987 | 679 | - | 456 | - | 602 | - | 556 | 408 | 309 |
| Glucose (mg/dL) | 117 | 127 | 133 | 130 | 98 | 83 | 93 | - | 87 | - |
| Triglycerides (mg/dL) | 292 | 156 | - | 387 | - | 236 | - | 212 | - | 307 |
| BNP (pg/mL) | 498 | - | - | 1181 | 1270 | 691 | 622 | - | - | 29 |
| CRP (mg/L) | 134.9 | 154.6 | 60.3 | 42.7 | 34.18 | 27.9 | 19.09 | 14.36 | - | 5 |
| Procalcitonin (ng/mL) | 33.9 | 78.7 | 89.5 | 33.29 | 9.45 | - | 1.27 | - | - | - |

**TABLE 1: Laboratory data for initial 10 days of admission**

WBC - white blood cells; Hgb - hemoglobin; ESR - erythrocyte sedimentation rate; PT - prothrombin time; PTT - partial thromboplastin time; BUN - blood urea nitrogen; AST - serum aspartate aminotransferase; ALT - alanine aminotransferase; LDH - lactate dehydrogenase; BNP - brain natriuretic peptide; CRP - C-reactive protein

Discussion
Management of MIS-C remains a challenge due to the evolving nature of this pandemic. A multi-disciplinary team is required to guide care. Due to the novelty of this condition, well-established treatment guidelines are not available; therefore, newly proposed institutional guidelines were utilized [8]. Clinical improvement and inflammatory markers reduction were adopted as markers for disease improvement. Our approach in pharmacological treatment was parallel to most institutions with IVIG, glucocorticoids, and interleukin receptor antagonists (Treatment guidelines: Montgomery V, Vidwan J, Statler V, et al.: EBC Guideline: Evaluation for Multisystem Inflammatory Syndrome - Children and Management of MIS-C. Norton Children’s hospital, 2020). Other institutions used biologic modifying agents only in patients unresponsive to IVIG and corticosteroids [5, 2]. Early development of shock with cardiac dysfunction has been the hallmark of MIS-C in acutely ill patients [3]. The positive outcome of this case emphasizes the importance of early recognition of shock state, proper and judicious fluid resuscitation, the early establishment of invasive monitoring, intubation, mechanical ventilation, and appropriate initiation of inotropes and vasopressors. Almost half of the patients presenting with MIS-C show some degree of ventricular dysfunction, pericardial effusion, or coronary aneurism. The rate of cardiac dysfunction without coronary involvement is much higher in MIS-C compared to KD [9]. Notably, patients with MIS-C have a higher prevalence of shock (76%) and cardiac dysfunction compared to Kawasaki disease (3%) [5]. Our patient showed noticeable bilateral atrioventricular (AV) valves regurgitation, which is a new finding compared to documented cases [10]. Persistence of cardiac dysfunction has been noticed in many cases on discharge [3]. This requires a close follow up of recovered patients with serial ECHOs. Concomitant cytokine storm in some patients with MIS-C makes it challenging to treat patients with only one clinical approach. There is not enough data for early prophylactic anticoagulation for the pediatrics population with MIS-C. In our patient with multiorgan failure and significant coagulation derangement, anticoagulation was justified. In some institutions, aspirin is used for initial anticoagulation, and low molecular weight heparin (LMWH) is only used in patients with noticeable elevation in D-dimer [3]. Further studies are warranted to investigate the pathophysiological mechanism of this post-infectious immune-mediated disease.

Conclusions
The unique about our case is the young age of the patient, unique cardiac involvement with valvar regurgitation, patient’s initial presentation with seizure, and response to our treatment protocol. Up to date, there is no approved treatment protocol for similar critical cases. It is important to share our experience with providers taking care of these newly evolving critical cases

Additional Information
Disclosures
Human subjects: Consent was obtained by all participants in this study. Conflicts of interest: In compliance with the ICMJE uniform disclosure form, all authors declare the following: Payment/services info: All authors have declared that no financial support was received from any organization for the submitted work. Financial relationships: All authors have declared that they have no financial relationships at present or within the previous three years with any organizations that might have an interest in the submitted work. Other relationships: All authors have declared that there are no other relationships or activities that could appear to have influenced the submitted work.

References
1. Belhadjer Z, Méot M, Bajoille F, et al.: Acute heart failure in multisystem inflammatory syndrome in children (MIS-C) in the context of global SARS-CoV-2 pandemic. Circulation. 2020, 142:399-406. 10.1161/CIRCULATIONAHA.120.048360
2. Whitaker E, Bamford A, Kenny J, et al.: Clinical characteristics of 58 children with a pediatric inflammatory multisystem syndrome temporally associated with SARS-CoV-2. JAMA. 2020, 324:259-269. 10.1001/jama.2020.10369
3. Capone CA, Subramony A, Sweeney T, et al.: Characteristics, cardiac involvement, and outcomes of multisystem inflammatory disease of childhood (MIS-C) associated with SARS-CoV-2 infection. J Pediatr. 2020, 224:141-145. 10.1016/j.jpeds.2020.06.044
4. Cheung EW, Zachariah P, Gorelik M, et al.: Multisystem inflammatory syndrome related to COVID-19 in previously healthy children and adolescents in New York City. JAMA. 2020, 324:294-296. 10.1001/jama.2020.10574
5. Chiotos K, Bassiri H, Behrens EM, et al.: Multisystem Inflammatory Syndrome in Children during the COVID-19 pandemic: a case series. J Pediatric Infect Dis Soc. 2020, 9:395-398. 10.1093/jipeds/piaa069
6. Pouletty M, Borocco C, Ouldail N, et al.: Paediatric multisystem inflammatory syndrome temporally associated with SARS-CoV-2 mimicking Kawasaki disease (Kawa-COVID-19): a multicentre cohort. Ann Rheum Dis. 2020, 79:999-1006. 10.1136/annrheumdis-2020-217960
7. Riphagen S, Gomez X, Gonzalez-Martinez C, Wilkinson N, Theechartis P: Hyperinflammatory shock in children during COVID-19 pandemic. Lancet. 2020, 395:1607-1608. 10.1016/S0140-6736(20)31094-1
8. Hennon TR, Perque MD, Abdul-Aziz R, et al.: COVID-19 associated Multisystem Inflammatory Syndrome in Children (MIS-C) guidelines; a Western New York approach. Prog Pediatr Cardiol. 2020, 57:101232. 10.1016/j.ppedc.2020.101232
9. Blondiaux E, Parisot P, Redheuil A, et al.: Cardiac MRI of children with multisystem inflammatory syndrome (MIS-C) associated with COVID-19: case series. Radiology. 2020, 329:107-108. 10.1148/radiol.2020202288
10. Dufort E, Koumans E, Chow E, et al.: Multisystem inflammatory syndrome in children in New York. N Engl J Med. 2020, 382:1009-1011. 10.1056/NEJMe2002456
